本帖最后由 老马 于 2012-1-13 21:20 编辑 + ~$ Z" ?0 y- q/ H% {: z* N5 O3 u% s
/ R- `/ R/ `3 N4 R ?1 S, J c: Z: G A
爱必妥和阿瓦斯丁的比较8 z. p. C% y5 u7 |* }: ~1 D
( P0 B$ r( t; lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
* x k7 X7 k# k+ x; B) ], _
, v/ [% ~$ |8 B
" a. K6 Z2 W/ k6 F7 @
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
7 g6 r3 Z% ~5 k5 L" b. r==================================================2 E3 W2 ?+ p* _/ z9 l
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Q) k; t+ W1 D5 c2 U; _
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, [7 x6 S: G3 e* H7 m. jResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. z4 S* I' q( w3 z
|